Fortress Biotech jumps as FDA clears first rare pediatric disease treatment

Fortress Biotech

13/01/2026 13:05

** Shares of drug developer Fortress Biotech FBIO.O rise 11.7% to $4.69 premarket

** Co says U.S. FDA has approved Zycubo, the first treatment for Menkes disease, a rare and often fatal genetic disorder affecting copper absorption in children

** FBIO's Zycubo, developed by Cyprium Therapeutics, is a daily injectable that restores copper levels

** Co says early treatment cut death risk by nearly 80% vs. untreated patients

** Cyprium will receive royalties and up to $129 million in milestone payments from Sentynl Therapeutics, which now handles development and sales of the drug

** Most common side effects are infections, seizures, anemia - FBIO

** As of last close, FBIO up ~81% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))